Analysts Set Zura Bio Limited (NASDAQ:ZURA) Target Price at $18.00

Shares of Zura Bio Limited (NASDAQ:ZURA) have been given an average rating of “Buy” by the six research firms that are currently covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $18.00.

A number of brokerages have commented on ZURA. Piper Sandler started coverage on shares of Zura Bio in a report on Friday. They issued an “overweight” rating and a $26.00 target price for the company. Oppenheimer reaffirmed an “outperform” rating and issued a $16.00 price target (down from $17.00) on shares of Zura Bio in a report on Monday, April 1st.

Insider Activity at Zura Bio

In related news, Director Amit Munshi purchased 159,744 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The stock was purchased at an average price of $3.13 per share, with a total value of $499,998.72. Following the completion of the acquisition, the director now owns 777,384 shares in the company, valued at $2,433,211.92. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders have purchased 170,926 shares of company stock valued at $534,998. 15.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zura Bio

Large investors have recently made changes to their positions in the stock. Armistice Capital LLC raised its holdings in shares of Zura Bio by 66.3% in the 3rd quarter. Armistice Capital LLC now owns 1,580,000 shares of the company’s stock valued at $10,428,000 after purchasing an additional 630,000 shares in the last quarter. Silverarc Capital Management LLC increased its position in Zura Bio by 152.5% in the 3rd quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock valued at $2,667,000 after acquiring an additional 244,040 shares during the period. Lynx1 Capital Management LP acquired a new stake in Zura Bio in the third quarter valued at about $65,000. Raymond James & Associates grew its holdings in Zura Bio by 14.0% during the third quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock worth $511,000 after acquiring an additional 9,481 shares during the period. Finally, Eisler Capital US LLC acquired a new stake in shares of Zura Bio in the third quarter valued at about $660,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Stock Up 6.0 %

Shares of ZURA opened at $4.62 on Friday. The company has a 50 day moving average price of $3.26 and a 200-day moving average price of $3.93. Zura Bio has a fifty-two week low of $2.00 and a fifty-two week high of $14.00.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.